Â鶹ŮÓÅ

Skip to main content

The independent source for health policy research, polling, and news.

Subscribe Follow Us
  • Trump 2.0

    Trump 2.0

    • Agency Watch
    • State Watch
    • Rural Health Payout
  • Public Health

    Public Health

    • Vaccines
    • CDC & Disease
    • Environmental Health
  • Audio Reports

    Audio Reports

    • What the Health?
    • Health Care Helpline
    • Â鶹ŮÓÅ Health News Minute
    • An Arm and a Leg
    • Health Hub
    • HealthQ
    • Silence in Sikeston
    • Epidemic
    • See All Audio
  • Special Reports

    Special Reports

    • Bill Of The Month
    • The Body Shops
    • Broken Rehab
    • Deadly Denials
    • Priced Out
    • Dead Zone
    • Diagnosis: Debt
    • Overpayment Outrage
    • Opioid Settlement Tracking
    • See All Special Reports
  • More Topics

    More Topics

    • Elections
    • Health Care Costs
    • Insurance
    • Prescription Drugs
    • Health Industry
    • Immigration
    • Reproductive Health
    • Technology
    • Rural Health
    • Race and Health
    • Aging
    • Mental Health
    • Affordable Care Act
    • Medicare
    • Medicaid
    • Children’s Health

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

TRENDING TOPICS:

  • Medicaid Work Mandate
  • Suicide Prevention
  • Community Health Workers
  • Rural Health Payout
  • Opioid Crisis

Morning Briefing

Summaries of health policy coverage from major news organizations

  • Email

Friday, Dec 15 2023

Full Issue

Mixed MRNA Vaccine Treatment Shows Long-Term Promise Against Melanoma

The experimental messenger RNA shot, when paired with Merck's Keytruda treatment, halved the chance of recurrence or death from melanoma after three years. CBS News explains how this mRNA tech is custom-built for each patient based on an analysis of their tumors.

An experimental messenger RNA cancer vaccine developed by Moderna and Merck & Co paired with Merck's Keytruda cut the chance of recurrence or death from melanoma by half after three years, showing that benefits demonstrated a year ago have held up over time. (Erman and Wingrove, 12/14)

Cambridge-based Moderna has used mRNA technology to develop an experimental melanoma vaccine which is custom-built for each patient based on analysis of their tumor once it's been surgically removed. The vaccine is designed to train the immune system to recognize and attack cancer cells throughout the body. (Marshall, 12/14)

In other scientific developments —

For years, Lauren Gavron relied on oxycodone to quiet the pain in her missing lower left limb. But she hated the fog that came with it, preventing her from feeling comfortable enough to drive. When researchers at the University of Pittsburgh delivered electric jolts to her spine in 2021, the Duquesne, Pennsylvania resident was shocked to feel that pain temporarily melt away — and to feel sensation in her prosthetic foot, improving her walk and balance. (Lawrence, 12/14)

Early risers may have inherited genetic variants from Neanderthals that increased their odds of being morning rather than evening people, new research has found. While the human body clock is a complex trait shaped by social and cultural norms as well as genetics, Neanderthals, who evolved at high latitudes in Europe and Asia for hundreds of thousands of years, may have been better adapted to seasonal variation in daylight compared with early Homo sapiens, or modern humans, according to a study published Thursday in the journal Genome Biology and Evolution. (Hunt, 12/14)

This is part of the Morning Briefing, a summary of health policy coverage from major news organizations. Sign up for an email subscription.
Newsletter icon

Sign Up For Our Newsletter

Stay informed by signing up for the Morning Briefing and other emails:

Recent Morning Briefings

  • Today, April 29
  • Tuesday, April 28
  • Monday, April 27
  • Friday, April 24
  • Thursday, April 23
  • Wednesday, April 22
More Morning Briefings
RSS Feeds
  • Podcasts
  • Special Reports
  • Morning Briefing
  • About Us
  • Republish Our Content
  • Contact Us

Follow Us

  • RSS

Sign up for emails

Join our email list for regular updates based on your personal preferences.

Sign up
  • Editorial Policy
  • Privacy Policy

© 2026 Â鶹ŮÓÅ